Please login to the form below

Not currently logged in

Pierre Fabre’s Braftovi gets EU okay for BRAF+ colorectal cancer

Drug is first to be specifically approved for this type of cancer in the EU

EMA logo

The EMA has approved Pierre Fabre’s Braftovi for the treatment BRAF-positive colorectal cancer, making it the first drug specifically approved for this type of cancer in the EU.

BRAF inhibitor Braftovi (encorafenib) has been cleared in a regimen alongside Merck KGaA’s EGFR-targeting antibody Erbitux (cetuximab) for second-line treatment of BRAF+ colorectal cancer patients previously treated with other systemic therapies.

Braftovi was approved for the same indication in April in the US, where it is sold by Pfizer – and was one of the key elements in the big pharma company’s $11.4bn takeover of Array Biopharma last year, particularly for its potential as a colorectal cancer treatment.

Braftovi is already approved to treat BRAF+ melanoma – a form of skin cancer – as a combination therapy with MEK inhibitor Mektovi (binimetinib), and analysts at EvaluatePharma think that colorectal cancer will account for more than $700m of the drug’s predicted global sales in 2024 of $1.2bn. Pfizer claimed approval for the colorectal cancer indication from the FDA in April.

The latest EU approval – which also covers the UK, Norway, Iceland and Liechtenstein – follows the BEACON CRC trial, which according to Pierre Fabre is the first and only phase 3 study to test a BRAF combination targeted therapy in BRAF+ colorectal cancer.

The results showed that Braftovi/Erbitux significantly improved overall survival (OS) by 40% compared to Erbitux and irinotecan-based chemotherapy, with a median OS of 9.3 months and 5.9 months, respectively.

Data from the trial also showed that the two-drug combination was as effective as a triple therapy which also included Mektovi, which meant that additional toxicity from the MEK inhibitor could be avoided without compromising patient benefits.

The trial has established Braftovi and Erbitux as a standard therapy for second-line BRAF-mutant colorectal cancer, but trials are already underway that will try to move the combination into the front-line setting.

The phase 2 ANCHOR CRC trial, which started in 2018 before the BEACON CRC results were mature, is testing triple therapy with Braftovi/Mektovi plus Erbitux or another EGFR inhibitor – Amgen’s Vectibix (panitumumab) – as a chemotherapy-free option for patients. It is due to generate results this month.

Colorectal cancer is the third most common cancer and the second leading cause of cancer-related deaths, with about 1.8m new  diagnoses globally, and of these 7-10% have BRAF mutations.

Novartis is also testing its BRAF/MEK combination of Tafinlar (dabrafenib) and Mekinist (trametinib) in BRAF-positive colorectal cancer, and recently started trials of the duo alongside other Novartis drugs, including its experimental PD-1 inhibitor PDR001, in this indication.

Article by
Phil Taylor

4th June 2020

From: Research, Regulatory, Healthcare



COVID-19 Updates and Daily News

Featured jobs


Add my company
Jet Off with Maloff Protect

Latest intelligence

A snapshot of… Exscientia
Patients are ready for virtual clinical trials, are you?
Traditional clinical trial designs simply can’t withstand the impact of COVID-19. While before the pandemic, some in clinical research were beginning to adopt virtual components, the move towards designing hybrid...
Keep your audiences close
How getting up close and personal with target audiences can fuel creativity...